CDG Therapeutics, Inc. is a Chicago-based biotechnology company engaged in the development and commercialization of proprietary peptides derived from pathogenic and nonpathogenic bacteria and green plants.
These peptides possess a unique ability to preferentially enter cancer cells and induce cell cycle arrest and ultimately cell death.
